


Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group

Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group

ACIP General Meeting
August 3, 2023



Work group members (External)

ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O'Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

Lucia Lee (FDA-CBER)

Robin Wisch (FDA-CBER)

Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

Kevin Ault (Western Michigan University)

GRADE/EtR Consultants

Doug Campos-Outcalt

Rebecca Morgan

Work group members (CDC)

CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Mila Prill

Natalie Thornburg

Aron Hall

Ismael Ortega-Sanchez

Melissa Coughlin

Jamison Pike

Lauren Roper

Amber Winn

Chris Taylor

Tami Skoff

Angie Campbell

Michael Melgar

Amanda Payne

Nicole Dowling

Noelle Molinari

Claire Midgley

Fiona Havers

Pragna Patel

Andrea Sharma

Amadea Britton

Ruth Link-Gelles

Danielle Moulia

Megan Wallace

Monica Godfrey

Karen Broder

Naomi Tepper

Heidi Moline

Hannah Rosenblum

Derrell Powers

Raigan Wheeler

Sally Ezra

Elizabeth Greene

Manisha Patel

Tom Shimabukuro

Demorah Hayes

Latifah Boyce

A. Patricia Wodi

Neil Murthy

Christine Olson

Anne Hause

Andrew Leidner

David Shay

Sarah Meyer

CDC ACIP Staff

Melinda Wharton

Stephanie Thomas

Jessica MacNeil

Previous maternal/pediatric RSV ACIP presentations on nirsevimab

- Epidemiology and burden of RSV in infants
- Virology and immunology of RSV
- Safety and efficacy of nirsevimab
- Cost effectiveness analysis for nirsevimab – CDC model
- Cost effectiveness analysis for nirsevimab – Comparison with manufacturer model
- Evidence to Recommendations framework for nirsevimab
- Clinical considerations for nirsevimab

Agenda: Thursday August 3, 2023

- Evidence to Recommendations Framework for nirsevimab Dr. Jefferson Jones (CDC)
- Nirsevimab implementation considerations Dr. Georgina Peacock (CDC)
- Clinical considerations for nirsevimab Dr. Jefferson Jones (CDC)
- Workgroup considerations and proposed recommendations and voting language Dr. Jefferson Jones (CDC)
- Vaccines for Children Resolution Dr. Jeanne Santoli (CDC)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Proposed ACIP Voting Language

- Infants aged <8 months born during or entering their first RSV season are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥5 kg)
- Children aged 8–19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of nirsevimab (200 mg)